Condensed Financial Information of Parent Company (Tables)

12 Months Ended

Dec. 31, 2022

Condensed Financial Information Disclosure [Abstract]

Schedule of Parent-only Balance Sheets

The following table presents the parent-only balance sheets of GoodRx Holdings, Inc.:

	December 31,
(in thousands, except par values)	2022			2021
Assets
Cash	$	5		$	5
Other asset		—			80
Investment in subsidiary, net of distributions		814,822			831,595
Total assets	$	814,827		$	831,680
Liabilities and stockholders' equity
Total liabilities	$	—		$	—
Stockholders' equity
Preferred stock, $0.0001 par value		—			—
Common stock, $0.0001 par value		40			40
Additional paid-in capital		2,263,322			2,247,347
Accumulated deficit		(1,448,535	)		(1,415,707	)
Total stockholders' equity		814,827			831,680
Total liabilities and stockholders' equity	$	814,827		$	831,680

Schedule of Parent-only Statement of Operations

The following table presents the parent-only statements of operations of GoodRx Holdings, Inc.:

	Year Ended December 31,
(in thousands)	2022			2021			2020
Equity in loss of subsidiary	$	(32,828	)	$	(25,254	)	$	(293,623	)
Net loss	$	(32,828	)	$	(25,254	)	$	(293,623	)

Schedule of Parent-only Statement of Cash Flows

The following table presents the parent-only statements of cash flows of GoodRx Holdings, Inc.:

	Year Ended December 31,
(in thousands)	2022			2021			2020
Cash flows from operating activities
Net loss	$	(32,828	)	$	(25,254	)	$	(293,623	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Equity in loss of subsidiary		32,828			25,254			293,623
Changes in assets and liabilities:
Other asset		80			(23	)		90
Other current liabilities		—			(87	)		87
Net cash provided by (used in) operating activities		80			(110	)		177
Cash flows from investing activities
Distribution from (investment in) subsidiary		113,117			22,777			(914,434	)
Net cash provided by (used in) investing activities		113,117			22,777			(914,434	)
Cash flows from financing activities
Proceeds from issuance of common stock in initial public offering, net of    underwriting discounts and commissions		—			—			891,793
Proceeds from private placement with a related party		—			—			100,000
Repurchases of Class A common stock		(101,721	)		—			—
Payments of initial public offering issuance costs		—			—			(4,937	)
Proceeds from exercise of stock options		9,159			35,021			5,343
Proceeds from early exercise of stock options		—			—			667
Employee taxes paid related to net share settlement of equity awards		(20,635	)		(57,688	)		(78,714	)
Net cash (used in) provided by financing activities		(113,197	)		(22,667	)		914,152
Net change in cash		—			—			(105	)
Cash
Beginning of period		5			5			110
End of period	$	5		$	5		$	5